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Important aspects of cell cycle regulation are the checkpoints, which respond to a variety of
cellular stresses to inhibit cell cycle progression and act as protective mechanisms to ensure
genomic integrity. An increasing number of tumor suppressors are being demonstrated to have
roles in checkpoint mechanisms, implying that checkpoint dysfunction is likely to be a common
feature of cancers. Here we report that histone deacetylase inhibitors, in particular azelaic
bishydroxamic acid, triggers a G2 phase cell cycle checkpoint response in normal human cells, and
this checkpoint is defective in a range of tumor cell lines. Loss of this G2 checkpoint results in the
tumor cells undergoing an aberrant mitosis resulting in fractured multinuclei and micronuclei and
eventually cell death. This histone deacetylase inhibitor-sensitive checkpoint appears to be distinct
from G2/M checkpoints activated by genotoxins and microtubule poisons and may be the human
homologue of a yeast G2 checkpoint, which responds to aberrant histone acetylation states.
Azelaic bishydroxamic acid may represent a new class of anticancer drugs with selective toxicity
based on its ability to target a dysfunctional checkpoint mechanism in tumor cells.
INTRODUCTION
A complex series of controls ensure ordered progression
through the cell cycle. Incomplete replication, the presence
of unrepaired DNA, or incorrect spindle assembly initiates
an arrest of cell cycle progression through a checkpoint
mechanism (Elledge, 1996). Checkpoints ensure that pro-
gression through key cell cycle phase transitions occurs only
after successful and accurate completion of the preceding
phase. Failures in these checkpoints can lead to the trans-
mission of a mutated genome, the consequence of either
incomplete replication, genetic mutations, or the loss or gain
of chromosomes, to future generations. These genetic aber-
rations may result in the loss of a growth suppressor or
acquisition of a growth promotor and usually accompany
further genomic instability, a hallmark of cancer (Hartwell
and Kastan, 1994; Lengauer et al., 1997). A number of genes
identified as tumor suppressors have important roles in
checkpoints, e.g., p53, Rb, and BRCA1, and loss or mutation
of tumor suppressor genes is a common feature in the de-
velopment of many types of cancer (Elledge, 1996; Sherr,
1996).
The primary components of the cell cycle machinery are
cyclin-dependent kinases (cdks). This family of related
serine-threonine kinases are regulated by association with
regulatory cyclin subunits and a series of phosphorylations
and dephosphorylations (Morgan, 1995). A further level of
cdk regulation is via the cyclin-dependent kinase inhibitor
proteins, which directly bind the cdks. Two families of
these proteins have been identified, the p21Waf1/Cip1 and
p16INK4/CDKN2A families (Sherr and Roberts, 1995). The
cdk/cyclins are the ultimate targets of the checkpoint path-
ways. This is best illustrated by the ionizing radiation–
induced G1 checkpoint, which is mediated by the tumor
suppressor gene product p53, which increases the expres-
sion of p21, in turn inhibiting cdk2/cyclin activity necessary
for progression from G1 into S phase (Dulic et al., 1994;
Wang, 1998). There are also DNA damage checkpoints in
G2, which are imposed through a block in the cdc25-depen-
dent activation of the mitotic cdk/cyclins (Gabrielli et al.,
1997; Wang, 1998), and an anaphase checkpoint that senses
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the correct assembly of the condensed chromosomes onto
the mitotic spindle and bipolar microtubule attachment of
the kinetochores (Sorger et al., 1997). Failure to do so results
in the cells arresting in mitosis rather than transiting into the
subsequent G1.
Loss of cell cycle checkpoints provides a growth advan-
tage for tumor cells, but paradoxically, it is also loss of a
protective mechanism. Thus cells with dysfunctional check-
points are also more sensitive to agents that would normally
trigger a response from the defective checkpoint. For exam-
ple, cells carrying a mutation in the ATM gene, which is
involved in checkpoint response to DNA damage induced
by genotoxins such as ionizing radiation, are more suscep-
tible to killing by these agents (Lavin and Shiloh, 1996). Thus
the identification of checkpoint genes, defining their normal
functions and the cellular stresses to which they respond,
has important implications for the development of new an-
ticancer treatments.
The anticancer potential of histone deacetylase inhibitors
has been widely acknowledged (Saito et al., 1999; Saunders
et al., 1999). These compounds block histone deacetylase
activity, resulting in a profound increase in the acetylation
state of the chromatin, which in turn affects chromatin struc-
ture and regulation of gene expression (Grunstein, 1997).
Histone deacetylase inhibitors block cell proliferation by
up-regulating the expression of the cdk inhibitor p21Cip1/
Waf1, inducing a G1 phase arrest and a differentiated pheno-
type in a range of tumor cell types (Sowa et al., 1997; Archer
et al., 1998; Richon et al., 1998; Saito et al., 1999; Saunders et
al., 1999). The histone deacetylase inhibitor azelaic bishy-
droxamic acid (ABHA) has been demonstrated to selectively
and permanently arrest the growth of a range of tumor and
transformed cell lines, without affecting normal cell lines
(Parsons et al., 1997; Qiu et al., 1999). ABHA is also a potent
differentiation-inducing factor (Breslow et al., 1991), al-
though in melanoma cell lines the only indication of differ-
entiation is a more dendritic morphology, other differentia-
tion markers being unaffected (Parsons et al., 1997). The
molecular basis of this selective toxicity is not attributable to
differential sensitivity of histone deacetylases in these cell
lines to inhibition by ABHA, because the levels of histone
acetylation observed after ABHA treatment were similar in
sensitive and resistant cell lines (Qiu et al., 1999). In this
report we have investigated the basis of the selectivity of
ABHA and uncovered a novel G2 checkpoint activated by
histone deacetylase inhibitors in resistant cells, which is
Figure 1. ABHA induces a G2/M ar-
rest in resistant cells. Cultures of
ABHA-resistant NFF and ABHA-sensi-
tive HeLa and MM96L cells were
treated with 100 mg/ml ABHA for the
indicated times and then harvested and
analyzed by FACS for their cell cycle
status. The percentage of subdiploid
(,2n), G1, S, and G2/M phase cells are
reported as mean 6 SD from three to
five separate experiments.
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defective in sensitive cells. The loss of this checkpoint ap-
pears to be a major determinant of the sensitivity to this class
of drugs, and the apparently widespread loss of this check-
point may account for the tumor cell selectivity of ABHA.
MATERIALS AND METHODS
Materials
Trichostatin A (TSA), sodium butyrate, hexamethylene bisacet-
amide (HMBA), etoposide, and nocodazole were purchased from
Sigma (St. Louis, MO). ABHA and azelaic-1-hydroxamate-9-anilide
(AAHA) were generously synthesized by Mike West (Center for
Drug Design and Development, University of Queensland). The
topoisomerase II inhibitor ICRF193 was a generous gift from Dr.
A.M. Creighton (St. Bartholemew’s Hospital, London, United King-
dom). All chemicals used were analytical grade.
Cell Lines and Culture Conditions
The human cervical cancer cell line HeLa, human melanoma cell
lines MM96L, SK-Mel-13, A2058, and MM229, and primary cultures
of neonatal foreskin fibroblasts (NFFs) were cultured in RPMI-1640
medium containing 5 or 10% (vol/vol) fetal calf serum. Assays for
Mycoplasma were carried out monthly to ensure that the cultured
cells were free of contamination. Asynchronous cultures of each cell
line were treated with 100 mg/ml ABHA, 100 ng/ml TSA, 10 mg/ml
AAHA, 5 mM sodium butyrate, or HMBA for 24 h and then har-
vested for immunoblotting, immunoprecipitation, or flow cytomet-
ric analysis. In some cases, cultures were treated with 0.5 mg/ml
ICRF193, 600 nM etoposide, or 0.5 mg/ml nocodazole for 24 h to
produce G2 or M phase–arrested populations.
3-[4,5-Dimthylthiazol-2yl]-2,5-Diphenyltetrazolium
Bromide (MTT) Cell Proliferation Assay
Cells in log phase growth were seeded into 96-well plates at a
density of 2–5 3 103 on the day before addition of 100 mg/ml
ABHA. Cell proliferation was measured using MTT, which mea-
sures mitochondrial activity of viable cells. MTT was added to the
culture media at a final concentration of 0.5 mg/ml, and the plates
were incubated for 4 h at 37°C. The insoluble Formazan product
was then precipitated by centrifuging the plates, the supernatant
was removed, and the Formazan crystals were dissolved in 100 ml of
DMSO with gentle shaking at room temperature. Absorbance at 570
nm was measured using a Bio-Rad (Hercules, CA) microplate
reader.
Cell Synchrony and Flow Cytometry
Cells were synchronized in late G1/early S phase by addition of 2
mM hydroxyurea for 24 h and then released from this block by
washing and addition of fresh media. ABHA or TSA was added 2 h
after release from the hydroxyurea block as the cells were progress-
ing through early S phase. Control untreated or treated cells were
harvested at 8, 12, 24, and 48 h after release from the hydroxyurea
block for either flow cytometry or biochemical analysis. Both at-
tached and floating cells were collected. For flow cytometric analy-
sis, cells were fixed in 70% ethanol at 0°C, and the nuclear DNA was
stained using a solution of propidium iodide (50 mg/ml), RNase A
(1 mg/ml), and Triton X-100 (0.02%) in PBS. The stained cells were
filtered through fine gauze, and the single-cell suspensions were
analyzed on a FACScalibur (Becton Dickinson, Franklin Lakes, NJ)
using CellQuest and ModFit data analysis software.
Asynchronous cultures were labeled with 10 mM bromodeoxyuri-
dine (BrdU) for 2 h, treated with 100 mg/ml ABHA for 24 h, and
then harvested and fixed with 70% ethanol at 220°C. The fixed cells
were suspended in 2 M HCl and 0.5% (vol./vol) Triton X-100 for 30
min at room temperature. The cells were neutralized by resuspend-
ing them in 0.1 M Na tetraborate, pH 8.5, for 5 min at room
temperature. BrdU incorporation was detected by staining with
FITC-conjugated anti-BrdU monoclonal antibody (Becton Dickson),
the DNA was counterstained with propidium iodide, and cells were
analyzed by two-dimensional flow cytometry.
Immunoblotting
Cell pellets were dispersed by sonication in 300 ml of cell lysis buffer
(20% glycerol, 1% SDS, 10 mM Tris, pH 7.4, and 2 mM PMSF), boiled
for 5 min, and then centrifuged at 15,000 rpm for 15 min to obtain a
clarified soluble fraction. Samples were stored at 270°C until use.
Protein quantitation was performed using bicinchoninic acid (Pierce,
Rockford, IL) using g-globulin as a standard. Samples were resolved
on 12% SDS-PAGE and then transferred to nitrocellulose membranes.
The levels of various cell cycle regulatory proteins were detected using
antibodies against Rb and cyclin A (PharMingen, San Diego, CA),
cyclin B1 and cdc25C (Gabrielli et al., 1996), cdc2 and cdk2 (Santa Cruz
Biotechnologies, Santa Cruz, CA), p21Cip1/Waf1 (Calbiochem, La Jolla,
CA), and p27Kip1 (Transduction Laboratories, Lexington, KY), detected
with the appropriate horseradish peroxidase-conjugated secondary an-
tibody using enhanced chemiluminescent (New England Nuclear, Bos-
ton, MA) detection. Equal amounts of protein (20 mg of protein) were
loaded, confirmed in some experiments by Coomassie blue staining of
a gel run in parallel.
Figure 2. ABHA induces proliferative arrest and cell death. MTT
assays were performed on the indicated cell lines over 72 h with or
without addition of 100 mg/ml ABHA. The data are the mean 6 SD
of triplicate determinations.
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Immunoprecipitation and cdk Kinase Assay
Cells (1–5 3 106) were lysed in NETN buffer (20 mM Tris, pH 8.0,
100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) supplemented
with 0.3 M NaCl, 5 mg/ml leupeptin, apoprotin, and pepstatin, 0.5
mM PMSF, 10 mM NaF, and 0.1 mM sodium vanadate. The cleared
lysates were incubated with anti-cdk2 and anti-cyclin B1 (1–2 mg of
antibody) antibodies prebound to 30 ml of 50% suspension of pro-
tein A-Sepharose for 3 h at 4°C. The precipitates were washed four
times with NETN and assayed for histone H1 kinase activity as
described previously (Gabrielli et al., 1997). The histone phosphor-
ylation was quantitated by PhosphorImager (Molecular Dynamics,
Sunnyvale, CA).
Immunofluorescent Staining
Cells were grown on glass coverslips. For immunostaining, cells
were washed with PBS and then fixed with 220°C methanol and
stored at 220°C until required. Coverslips were fixed to a glass
microscope slide, allowed to air dry, and then rehydrated with PBS
containing 0.1% Tween 20 and 3% BSA for 1 h at room temperature.
The cells were stained with anti-a-tubulin (1:1000 dilution; Amer-
sham, Arlington Heights, IL) and human autoimmune serum to
detect kinetochores (1:500 ACA serum; a gift from Dr. J.B. Rattner,
University of Calgary, Calgary, Alberta, Canada) and DAPI for
DNA. Photomicroscopy was performed as described previously
(Gabrielli et al., 1996).
RESULTS
Histone Deacetylase Inhibitors Impose G1 and G2/
M Phase Cell Cycle Arrest
We have examined a number of cultured cell types with
varying sensitivity to killing by ABHA: ABHA-resistant NFF
Figure 3. Treatment with a range of histone
deacetylase inhibitors produces similar cell cycle
effects. Cultures of the indicated cell lines, either
asynchronously growing controls (Con) or treated
with 5 mM HMBA, 5 mM sodium butyrate, or 10
mg/ml AAHA and then harvested after 24 h, were
analyzed by FACS for their cell cycle status as in
Figure 1. These data are representative of three
separate experiments.
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cultures (D37 .300 mg/ml) and MM229 (D37 180 mg/ml),
ABHA-sensitive HeLa, A2058, and SK-Mel-13 cell lines (D37
,50 mg/ml), and hypersensitive MM96L (D37 10 mg/ml)
(Parsons et al., 1997). Only data from experiments with a
representative cell line from each sensitivity group, NFF,
HeLa, and MM96L, are shown, although essentially identi-
cal results were obtained with the other cell lines in each
group.
A difference was observed in the cell cycle distributions of
ABHA-sensitive tumor cells and ABHA-resistant cultures
after treatment with a dose (100 mg/ml) of ABHA that was
toxic to the tumor cells lines, whereas NFF cells were resis-
tant to killing at this concentration (Parsons et al., 1997). NFF
cultures showed an increased G2/M population at 24 and
48 h and an emptying of the S phase compartment (Figure
1). These cell cycle changes are indicative of arrests in G1
and G2/M phases of the cell cycle. Loss of S phase cells was
also observed in ABHA-treated HeLa cultures, but there was
no evidence of a G2/M phase accumulation, suggesting only
a G1 phase arrest. By contrast, ABHA reduced the propor-
tion of G1 phase cells in cultures of MM96L at 24 h, and
there was a significant increase in the proportion of subdip-
loid cells (,2n DNA content), likely to be dying cells (Dar-
zynkiewicz et al., 1992), although the persistence of an S
phase population suggests that some proportion of these
cultures were still actively cycling. By 48 h, .90% of MM96L
cells had ,2n DNA content, and .40% HeLa cells were
subdiploid, whereas only 20% of the NFF cells were subdip-
loid at this time (Figure 1). [3H]Thymidine incorporation
studies confirmed the loss of S phase cells in ABHA-treated
NFF and HeLa cultures at 24 h after treatment. ABHA
treatment also reduced the levels of [3H]thymidine incorpo-
ration in MM96L cells to 30% of controls, indicating that a
reduced proportion of cells were in S phase, supporting the
fluorescence-activated cell sorting (FACS) data (our unpub-
lished results).
To confirm that the increase in the subdiploid population
observed in the ABHA-treated tumor cells was due to dying
cells, MTT proliferation assays were performed. NFF cul-
tures cycled normally until 24 h after treatment and then
arrested, whereas MM96L cultures had reduced prolifera-
tion, and HeLa cells were completely blocked at this time
(Figure 2). For both HeLa and MM96L cultures, the viable
population decreased at 48 h after treatment to levels below
those at the start of the experiment, and by 72 h there was
complete loss of viability in the tumor cell lines (Figure 2).
The reduction in the numbers of viable cells in the tumor cell
cultures correlated with the increased proportion of subdip-
loid cells observed by FACS (Figure 1).
Other histone deacetylase inhibitors, sodium butyrate and
the ABHA derivative AAHA, were also found to have a
similar spectrum of cell cycle effects as ABHA in both nor-
mal and tumor cell cultures. The related compound HMBA,
which does not inhibit histone deacetylase activity (Richon
et al., 1998), only partly reduced the S phase population and
did not produce a G2/M arrest in NFF cultures but actually
reduced the proportion of G2/M phase cells (Figure 3).
The changes in cell cycle distribution detected by flow
cytometry suggested that ABHA treatment imposed a G1
phase arrest in NFF and HeLa cells but not MM96L cells.
This was confirmed by analysis of the G1/S regulators Rb
and cyclin A/cdk2. Immunoblotting of lysates from equal
numbers of either untreated control or ABHA-treated cells
at 24 h after treatment revealed no changes in Rb protein
levels but a loss of the hyperphosphorylated forms of Rb in
ABHA-treated HeLa and NFF cells, detected by the reduc-
tion from multiple to a single, tight electrophoretic species,
consistent with the G1 arrest observed in NFF and HeLa
cells (Figure 1). No change in Rb was noted in MM96L cells,
which do not arrest in G1 (Figure 3). No changes were
observed in the levels of cdk2, but its partner cyclin A was
down-regulated in HeLa and NFF cells. The cdk inhibitor
p21 was increased in both HeLa and NFF cells but not in
MM96L cells (Figure 4A), and no effect on the levels of two
other cdk inhibitors, p16 and p27, was observed (our un-
published results).
Figure 4. ABHA treatment affects the expression and activity of
cell cycle regulators. (A) Cells were treated with 100 mg/ml ABHA
as indicated and harvested after 24 h, lysed, and immunoblotted for
the indicated cell cycle regulatory proteins. The positions of the
hyper- and hypophosphorylated forms of Rb and cdc2 are indicated
by the arrowheads. (B) Cdk2 immunoprecipitate H1 kinase activity
was assessed from cells treated as in A. No phosphorylation of H1
was detected in the ABHA-treated NFF sample even on longer
exposures.
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The activity of the cdk2/cyclin A complexes, which have
functions in S and G2/M phases of the cell cycle (Dulic et al.,
1992; Rosenblatt et al., 1992; Pagano et al., 1993), reflected the
increased p21 and decreased cyclin A levels. The cdk2 ac-
tivity was undetectable in NFF cultures and strongly sup-
pressed in HeLa cells (5% of control levels) after ABHA
treatment, whereas the ABHA-treated MM96L cells had sim-
ilar activity to the controls (Figure 4B). Taken together, these
Figure 5.
L. Qiu et al.
Molecular Biology of the Cell2074
data support the cell cycle arrests in both NFF and HeLa cell
cultures observed by FACS at 24 h after treatment with
ABHA and the lack of arrest in MM96L cultures (Figure 1).
The levels of G2/M regulatory proteins revealed little
effect on either the levels or phosphorylation status of cdc2
as detected by electrophoretic mobility shift (Figure 4A) or
immunoblotting with a cdc2 and cdk2 phosphotyrosine 15-
specific antibody (our unpublished results). The level of
cyclin B1 was reduced in HeLa cells (Figure 4A). Interest-
ingly, the level of cdc25C, one of the activators of cdc2/
cyclin B in mitosis, was greatly reduced in both HeLa and
MM96L cells but unaffected in NFF cells. The loss of cdc25C
expression in both tumor cell lines suggests that these cells
would be incapable of reentering a second round of mitosis
after 24 h ABHA treatment.
Absence of a G2 Arrest Correlates with Increased
Sensitivity to ABHA
The accumulation of cells with 4n DNA content in the
ABHA-treated NFF cultures suggested that these cells were
arrested in G2/M, and the lack of this accumulation in the
tumor cells may be due to either the lack of a G2/M arrest or
cells dying before reaching G2/M. Cultures were synchro-
nized using a hydroxyurea block release to examine whether
cells were capable of transiting through G2/M in the pres-
ence of ABHA. In each case, the untreated control cells
transited through S into G2 phase by 8 h with .60% syn-
chrony (NFFs were the exception, with up to 50% of cells
failing to exit the G1 arrest; see the 8-h time point in Figure
5A), reached mitosis by 10–12 h after release, and had re-
turned to asynchronous cycling by 24–48 h after release
(Figure 5, A–C). The ABHA-treated NFF cultures appeared
blocked in G1 and G2/M at 24 h, with the G1 cells likely to
be those that did not recommence cycling after the hy-
droxyurea block (Figure 5A). ABHA treatment of both tu-
mor cell lines slowed their progression through G2/M, dem-
onstrated by the greater accumulation of 4n cells compared
with the controls at 12 h after release (Figure 5, B and C). The
cells did, however, progress through mitosis, demonstrated
by the reduction in the 4n population at 24 h. The cell cycle
effects produced by ABHA were due to its histone deacety-
lase inhibitor activity, because substitution with 100 ng/ml
trichostatin A produced essentially identical results (our
unpublished results).
A striking consequence of ABHA treatment of the syn-
chronized tumor cells was the increase in the proportion of
subdiploid cells detected at 24 and 48 h after release from the
hydroxyurea block. In HeLa and MM96L cultures there was
an approximately twofold increase in the proportion of sub-
diploid cells detected at 24 h after release compared with
24 h after treatment of asynchronous cultures (increased
from 28 to 47% in HeLa and 50 to 77% in MM96L for
asynchronous and synchronous treatment, respectively; Fig-
ures 1 and 5). At 48 h after release, ABHA treatment resulted
in up to 100% subdiploid cells in both cell lines. ABHA
treatment of unsynchronized HeLa cultures resulted in only
75% cells with ,2n DNA content after 72 h. A similar,
although smaller, effect was observed with synchronized
NFF cultures, with ,35% subdiploid cells compared with
100% in the tumor cell cultures at 48 h, and appeared to
correlate with the decrease in G1 phase cells (Figure 5A).
The increased subdiploid population did not appear to be a
consequence of some inherent toxicity of hydroxyurea treat-
ment, because in some experiments a thymidine block re-
lease protocol was used to synchronize HeLa cell cultures in
place of hydroxyurea, and ABHA treatment produced a
similar increase in cell death at 24 and 48 h.
As a further measure of cell cycle progression through
mitosis, the activity of the mitotic cyclin/cdk activities, cy-
clin A/cdk2 and cyclin B1/cdc2, was assayed from the
synchronized cultures at 12 h after release. The mitotic cy-
clin/cdk activity in the ABHA-treated tumor cell samples
was .60% of the control levels, whereas little or no activity
was detected in the ABHA-treated NFF cultures (Figure 5D).
FACS analysis indicated that the tumor cell lines were re-
Figure 5 (facing page). Sensitive but not resistant cells transit
through mitosis in the presence of ABHA. (A–C) Cells were syn-
chronized at G1/S by overnight treatment with hydroxyurea (HU)
and then released from the arrest and treated without (Con) or with
100 mg/ml ABHA (ABHA) 2 h after release. Cells were harvested at
the indicated times after release and analyzed by FACS for their cell
cycle status as in Figure 1. The 8-h control time point is shown as a
measure of the synchrony obtained. The data presented are repre-
sentative of three to five separate experiments. Identical data were
obtained using 100 ng/ml TSA in place of ABHA (our unpublished
results). (D) The activity of cyclin A/cdk2 and cyclin B1/cdc2 was
assessed by anti-cdk2 and anti-cyclin B1 immunoprecipitate kinase
assays from samples of the indicated cell lines harvested at 12 h after
release from a hydroxyurea block and treated without or with 100
mg/ml ABHA as in A–C. The autoradiogram of the phosphorylated
histone H1 and activity expressed as percentage of the control for
each cell line are shown.
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tarded through G2/M, and visual inspection of cultures for
the rounded mitotic phenotype confirmed that ABHA treat-
ment delayed entry into mitosis by 1–2 h in the tumor cell
lines. This slowdown in G2/M progression is likely to ac-
count for the reduced cyclin/cdk activity in the ABHA-
treated tumor cells. The complete absence of both cyclin
A/cdk2 activity, which is activated in early G2 phase, and
cyclin B1/cdc2, which is activated at the G2/M transition,
and the absence mitotic cells in ABHA-treated NFF cultures
confirmed the G2 arrest in NFF cells observed by FACS
(Figure 5A).
Progression of the ABHA-treated HeLa cells, but not NFF
cells, through G2/M was also observed by following BrdU-
labeled S phase cells from asynchronously growing cultures.
Control cultures of NFF and HeLa cells displayed normal
progression through S into G2/M phase by 6 h and pro-
gressed into G1 and S phase again by 24 h after BrdU
labeling (Figure 6, A and B, Con). In ABHA-treated NFF
cultures, BrdU-labeled cells accumulated in the 4n peak at
6 h and remained blocked there at 24 h, whereas a large
proportion of the 4n population in ABHA-treated HeLa
cultures detected at 6 h had returned to the 2n peak by 24 h,
indicating that these cells have undergone mitosis and cy-
tokinesis (Figure 6B).
Lack of ABHA-sensitive G2 Arrest Leads to
Aberrant Mitosis
These data correlated the absence of an ABHA-induced
G2/M arrest in the tumor cell lines with increased sensitiv-
ity to killing by histone deacetylase inhibitors and the G2
arrest in NFF cells with protection from the cytotoxic effects
of ABHA. This is reminiscent of the loss of a cell cycle
checkpoint. Loss of the G2/M checkpoint is associated with
cells undergoing some form of aberrant mitosis and result-
ant daughter cells containing fractured DNA often seen as
micronuclei and eventually cell death (Jin et al., 1996; Rhind
et al., 1997). To examine whether the absence of a G2/M
arrest in the ABHA-treated tumor cells produced a similar
aberrant mitotic phenotype, hydroxyurea synchronized
cells, both control and ABHA treated, were fixed when
rounded mitotic cells were observed, 12–14 h after release
from the hydroxyurea block. The cells were stained for
microtubules, kinetochores, and DNA and inspected by flu-
orescence microscopy (Figure 7). In the control cultures,
metaphase and anaphase figures we observed, showing nor-
mal chromosome condensation and migration to the meta-
phase plate, and undergoing anaphase–telophase separation
of sister chromatids (Figure 7, a–c). Staining for kinetochores
showed the metaphase and anaphase movement of chromo-
somes very clearly (Figure 7b). In the ABHA-treated cells,
chromosome condensation and mitotic spindle formation
appeared to be relatively normal (Figure 7, d and f). How-
ever, few cells were observed with a properly formed meta-
phase plate, and most appeared to have some defect in
chromosomal congression, and it was common to see cells
with chromosomes surrounding the spindle poles and ki-
netochores on the astral side of the spindle pole (Figure 7, e
and f). A similar noncongression phenotype was found in
ABHA-treated asynchronous cultures and in two other mel-
anoma cell lines, SK-Mel-13 and A2058. Quantitation of the
noncongression phenotype in HeLa and MM96L cultures
revealed that .80% of the mitotic cells in the ABHA-treated
cultures displayed this form of aberrant mitosis (Figure 7G).
No mitotic figures were found in ABHA-treated NFF cul-
tures, and all had an interphase appearance.
The consequence of noncongression was cells undergoing
mitosis without proper partitioning of the replicated chro-
mosomes, resulting in cells containing multiple nuclei and
mini nuclei (Figure 8, b, c, and f, m), and in some cases the
cells had attempted to undergo cytokinesis with incom-
pletely separated chromosomes resulting in the classical
“cut” phenotype (Figure 8e, c), characteristic of a loss of
G2/M checkpoint arrest in yeast (Rhind et al., 1997). There
was also evidence of apoptosis, with cells displaying multi-
ple, brightly stained micronuclei characteristic of apoptosis
(Figure 8 e and f, a).
ABHA Triggers a Novel G2 Checkpoint
The absence of a G2 arrest and the consequent aberrant
mitotic phenotype and increased sensitivity to killing by
ABHA in the tumor cell lines indicated that a G2 checkpoint
mechanism responsive to histone deacetylase inhibitors was
defective in these cell lines. To establish whether this was
one of the characterized G2/M checkpoints, the tumor cell
lines were treated with a range of agents that trigger G2/M
arrest. The topoisomerase II inhibitors ICRF193 and etopo-
side trigger DNA catenation and strand break-sensitive
G2/M arrests, respectively (Lock, 1992; Downes et al., 1994),
and the microtubule poison nocodazole triggers an an-
aphase arrest (Sorger et al., 1997). These agents all induced
accumulation of cells with 4n DNA and G2/M arrest in all
the tumor cell lines (Figure 9). Progression through G2/M in
the presence of histone deacetylase inhibitors clearly dis-
rupted normal mitotic processes and led to cell death, indi-
cating that cell cycle progression, particularly through
G2/M, was at least partly responsible for the toxic effect of
ABHA. Thus imposition of a G2 arrest independently of
ABHA should rescue the checkpoint defect in HeLa and
MM96L cells. To test this, hydroxyurea-synchronized HeLa
cell cultures were treated with ABHA, ICRF193 was added
to induce a G2 arrest, and then the cell cycle distribution was
assessed at 24 h after release from hydroxyurea. The topo-
isomerase II inhibitor arrested the cultures in G2 phase and
significantly reduced the subdiploid population compared
with those treated only with ABHA (31 compared with 60%;
p . 0.01) to similar levels as ICRF193 treatment alone (Fig-
ure 10, A and B). To demonstrate that this rescue was a
consequence of the introduction of a G2 phase arrest rather
than simply an accumulation of cells with 4n DNA content
because of a block in cytokinesis, a similar experiment was
performed using nocodazole, which will block cytokinesis.
Nocodazole failed to reduce the proportion of the subdip-
loid cells compared with ABHA alone (Figure 10A).
A High Proportion of Tumor Cell Lines Are
Defective for the ABHA-sensitive G2 Checkpoint
A panel of 20 other cell lines have been tested for their cell
cycle response and sensitivity to killing by ABHA. These
represent immortalized lines, e.g., HaCaT and EBV im-
mortalized lymphoblastoid cell lines (eight lines were
tested, but only two representative lines are shown), and
a variety of virally transformed and tumor cell lines. Of
these, only two lines, MM229 and the Burkitts lymphoma
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line DG75, have been found to be resistant to killing by
100 mg/ml ABHA, and both displayed a strong G2/M
accumulation at 24 and 48 h after ABHA treatment (Table
1). The remaining cell lines were all sensitive to killing by
ABHA, with 60 –100% of cells containing ,2n DNA by
48 h after treatment. A few of these cell lines showed
Figure 6. Sensitive but not resistant
cells undergo cell division after ABHA
treatment. Asynchronous cultures of
NFF and HeLa cells were labeled
with BrdU for 2 h and then either
harvested immediately or 6 and 24 h
later, either without or with treat-
ment with 100 mg/ml ABHA. The
BrdU-labeled cells (those above the
dotted line) pass from S phase (Con,
0 h) into G2/M by 6 h and G1 phase
by 24 h (the BrdU-positive cells with
2n DNA content) in the untreated
controls and ABHA-treated HeLa
cells. No BrdU-labeled G1 phase
cells were detected in ABHA-treated
NFF cultures at either time.
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Figure 7. Cells attempting mitosis in the presence of ABHA
undergo aberrant mitosis. HeLa cells synchronized by hydroxyu-
rea block and then released and treated without (a–c) or with 100
mg/ml ABHA (d–f), as in Figure 5, were fixed as the cultures
entered mitosis. Cells were stained for DNA (a and d), kineto-
chores (b and e), and microtubules (c and f). The normal congres-
sion of condensed chromosomes at metaphase and partitioning at
anaphase are clearly observed with the kinetochore staining (a–c).
The ABHA-treated mitotic cells contained well-formed spindles,
but kinetochore and DNA staining shows chromosomes failing to
migrate to the midline of the cell (d–f). Bar, 10 mm. (G) Quantita-
tion of the aberrant mitosis in control and ABHA-treated samples.
The numbers of normal and abnormal mitoses were counted for
HeLa and MM96L cultures. In each case, between 100 and 200
mitotic figures were counted.
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small increases in the G2/M population at 24 h, e.g.,
A2058, SVMR, and SCC25, although these were likely to
represent multinuclear cells (see Figure 8) and were lost to
the subdiploid compartment by 48 h.
DISCUSSION
Histone deacetylase inhibitors have been demonstrated to
impose a G1 phase arrest as a result of up-regulated p21
Figure 8. ABHA-induced aberrant mitosis leads to de-
fective cytokinesis and death. MM96L (a–c) and HeLa
(d–f) cultures, either control (a and d) or treated for 24 h
with 100 mg/ml ABHA (b, c, e, and f) from a hydroxyu-
rea synchrony experiment as in Figure 6, were stained
with DAPI for DNA. The presence of multinuclear (m),
cut phenotype (c), and apoptotic cells (a) was confirmed
by counterstaining for microtubules. Bar, 10 mm.
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expression (Kiyokawa et al., 1994; Richon et al., 1996; Archer
et al., 1998; Saito et al., 1999). This is also observed in ABHA-
treated HeLa and NFF cells, with G1 arrest associated with
increased p21 expression and dephosphorylation of Rb and
the absence of G1 arrest in MM96L cells, correlated with the
absence of p21 expression and maintenance of Rb phosphor-
ylation and cdk2 activity. Down-regulation of cyclin A and
cyclin B1 expression observed with ABHA treatment in the
resistant NFF cells has also been reported in cells arrested in
G2/M after sodium butyrate treatment (Lallemand et al.,
1999) and appears to be a consequence of prolonged arrest in
G2. The down-regulation of cyclins and cdc25C expression
in the tumor cell lines is also likely to be a delayed effect,
because the synchrony experiments demonstrate that
ABHA-treated tumor cells maintain normal expression (our
unpublished data) and function of these proteins, indicated
by the presence of mitotic cells in the treated cultures. The
loss of cyclin and cdc25C expression is likely to reinforce the
proliferative arrest.
The data presented in this report support the existence of
a G2 checkpoint in ABHA-resistant cells, which is defective
in a panel of tumor cell lines. The accumulation of cells with
4n DNA content, the absence of any mitotic figures, and the
lack of mitotic cyclin/cdk activity in the synchronized,
ABHA-treated NFF cultures are clear evidence of a G2 ar-
rest. The absence of G2 arrest assessed by FACS, apparently
normal activation of mitotic cyclin/cdk activities, and high
frequency of aberrant mitoses observed in the ABHA-
treated tumor cells studied here are good evidence that the
ABHA-sensitive cell lines are defective for this protective G2
checkpoint. Reintroduction of a G2 arrest with the topoisom-
erase II poison ICRF193 had a protective effect, further sup-
porting the notion of a defective checkpoint function in the
ABHA-sensitive cells. The ABHA-initiated G2/M check-
point appears to be different from other known G2 check-
point mechanisms imposed in response to DNA catentation
defects, strand breaks, and spindle defects, because the
ABHA-sensitive cell lines examined retained these check-
point responses but not the histone deacetylase inhibitor-
sensitive G2 arrest.
The selective toxicity of ABHA therefore appears to be
based on the integrity of the histone deacetylase inhibitor-
sensitive G2 checkpoint. For example, the G2 checkpoint
was intact in NFF, MM229, and DG75 cells, and these cells
were relatively insensitive to the toxic effects of ABHA, with
only a small proportion of subdiploid cells by 48 h after
treatment. Another group has reported an osteosarcoma cell
line that displayed a G2/M arrest after treatment with TSA,
and this cell line was also relatively insensitive to killing
compared with another tumor cell line that did not G2/M
arrest in response to this agent (Sowa et al., 1997). The G1
arrest in response to ABHA in a number of ABHA-sensitive
tumor cell lines (HeLa, A2058, SK-Mel-13, and HT144) only
delayed the appearance of subdiploid cells by 24 h, and
these cell lines were .60% subdiploid at 48 h after treat-
ment, compared with cell lines that displayed no cell cycle
stage-specific arrest (MM96L, HaCaT, the LCL lines, KJD,
SVMR, SCC25, OvCar, and BL30K), which were .50% sub-
diploid by 24 h after treatment (Table 1).
The loss of the histone deacetylase inhibitor-sensitive
checkpoint results in the cells attempting to undergo mitosis
in an inappropriate state, leading to noncongression of the
condensed chromosomes and ultimately missegregation at
cytokinesis. It is surprising that despite the chromosome
noncongression observed in the ABHA-treated tumor cells,
they do not block in mitosis because of the imposition of an
anaphase spindle assembly checkpoint (Sorger et al., 1997)
but appear to continue through into G1 phase. This pheno-
type is typical of mutations in BUB1, MAD2, and CENP-E,
which are all kinetochore proteins involved in establishing
the anaphase checkpoint arrest (Schaar et al., 1997; Taylor
and McKeon, 1997; Waters et al., 1998). The spindle check-
point function appears to be intact in the cell lines used in
this study, because they all block in mitosis when treated
with nocodazole, and this may indicate that ABHA affects
the expression or function of components of the anaphase
checkpoint pathway, e.g., the BUBs and MADs.
The aberrant mitosis is likely to be a trigger for death in
the ABHA-treated tumor cells. The ABHA-induced arrest
in the resistant cells is in G2 phase, premitotic, before the
activation of cyclin A/cdk2 in early G2 phase and cyclin
B/cdc2 at G2/M, and this arrest is clearly defective in the
ABHA-sensitive cells. Reintroducing a G2 arrest using
ICRF193 reduced the level of cell death after ABHA treat-
ment, providing further support for the protective role of
Figure 9. ABHA-sensitive cell lines have functional G2/M check-
points. Asynchronously growing cultures (Con) or cultures treated
with ICRF193 (ICRF) or nocodazole (Noco.) were harvested after
24 h and analyzed by FACS for cell cycle status. In each case, the
drugs produced prominent G2/M accumulation with both tumor
cell lines. Similar experiments were performed with the topoisom-
erase II poison etoposide, which produced results similar to those of
the topoisomerase II poison ICRF193 (our unpublished results).
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the G2 arrest. However, it is also clear that ABHA dis-
rupts the mitotic spindle checkpoint in the ABHA-sensi-
tive lines. The relationship between the defective G2 ar-
rest and disruption of the later mitotic spindle checkpoint
in these cells is unclear, although they may possibly be
related. A precedent for a connection between the earlier
G2 checkpoint and the later mitotic checkpoint does exist.
The caffeine-induced bypass of etoposide-induced G2/M
arrest results in disruption of normal chromatid disjunc-
tion during mitosis in mammalian cells and catastrophic
fracturing of the chromosome by the mitotic spindle dur-
ing mitosis (Lock et al., 1994). Examination of the mitotic
figures in similar caffeine bypass experiments reveals a
noncongression phenotype very similar to that observed
with ABHA treatment of sensitive cells (our unpublished
observations). Thus, it may be that dysfunction of the G2
checkpoint may also disrupt the later mitotic spindle
checkpoint, ensuring that cells with significant DNA dam-
age die.
What is the nature of the ABHA-sensitive G2 check-
point, and how is it inactivated in the tumor cell lines?
One possibility is that ABHA alters the expression of a
gene or genes involved in G2/M progression, which re-
sults in the G2 arrest in resistant cells, and the regulator of
this transcriptional program is defective in the ABHA-
sensitive cells. An alternative mechanism is a response to
the dramatic increase in histone acetylation observed after
ABHA treatment of both sensitive and resistant cells (Qiu
et al., 1999). This mechanism would prevent cells entering
mitosis with hyperacetylated chromatin, which may in
turn affect centromere and kinetochore function and
thereby disrupt the spindle checkpoint. There may be a
defect in either the sensing or signaling mechanism in the
tumor cells that results in the loss of the ABHA-sensitive
checkpoint arrest. In yeast, TSA has been shown to cause
chromosome loss and to disrupt the localization of Swi6p,
normally localized to centromeres and involved in normal
sister chromatid disjunction (Ekwall et al., 1997). This
effect is related to hyperacetylation of centromeric his-
tones and results in missegregation of chromosomes dur-
ing mitosis. It has also been demonstrated that mutation
of the amino-terminal lysine residues normally acetylated
in histone H4 results in a G2/M arrest (Megee et al., 1995),
and mutations in one of the chromatin remodeling com-
plexes also produces a G2/M arrest and affects the chro-
matin structure around centromeres (Tsuchiya et al.,
1998). Thus in lower eukaryotes a checkpoint mechanism
exists that senses the acetylation state of the chromatin
and centromere integrity, which consequently may dis-
rupt normal kinetochore function. Considering the high
degree of conservation of cell cycle mechanisms from
yeast to human, it is likely that the ABHA-sensitive G2
checkpoint we have described here is related to the chro-
matin acetylation state-sensitive G2/M checkpoint in
yeast.
These findings may have clinical relevance in that
ABHA represents a novel class of potent chemotherapeu-
tic agents, which selectively kill transformed and tumor
cells with defective checkpoint functions. Our initial find-
ings suggest that the ABHA-sensitive cells types may
represent a high proportion of epithelial and epidermally
derived tumors. The identification of the molecular basis
of action of ABHA and its selectivity, especially identifi-
cation of mutation and deletions of genes that result in the
loss of the checkpoint responses in sensitive cells, may
Figure 10. Activation of a G2 checkpoint reduces ABHA-induced cell death. (A) HeLa cells were synchronized by hydroxyurea block release
as in Figure 5, treated with ABHA (ABHA), ICRF193 (ICRF), or nocodazole (Noco.), or added in combination as indicated, 2 h after release,
and then harvested at 24 h. (B) Proportion of subdiploid cells at 24 h from five independent experiments similar to those in A, with no
addition (HU), ABHA only, ICRF193 only, or coaddition of ABHA and ICRF193.
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lead to more effective treatment of tumors by more di-
rectly targeting the checkpoint.
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